介入超声下聚桂醇与无水乙醇治疗肝囊肿患者临床效果对比观察  

Comparative observation of clinical effects of lauromacrogol and absolute ethanol in patients with liver cysts under interventional ultrasound

作　　者：黄海宁[1] HUANG Haining(The First People’s Hospital of Huizhou City, Huizhou 516001, China)

机构地区：[1]惠州市第一人民医院超声科,广东惠州516003

出　　处：《包头医学院学报》2020年第2期38-40,共3页Journal of Baotou Medical College

摘　　要：目的:对比分析介入超声下聚桂醇与无水乙醇治疗肝囊肿患者临床效果。方法:选取2018年1月至2019年6月收治的78例肝囊肿患者随机分为A、B组,A组给予介入超声下注入聚桂醇硬化治疗,B组给予介入超声下注入无水乙醇硬化治疗,比较两组临床疗效、临床指标、治疗前后肝功能指标及不良反应发生情况。结果:A组患者临床疗效总有效率为97.44%较B组76.92%显著性提高,液体抽取量(93.78±7.21)mL较B组(80.00±7.18)mL显著增加,治疗时间(4.69±0.65)d较B组(7.52±0.62)d显著缩短,治疗费用(4328.27±723.44)元较B组(4988.98±700.52)元显著降低,差异均具有统计学意义(P<0.05);治疗前两组患者肝功能指标无显著性差异(P>0.05),治疗后两组患者ALP、AST、CHE指标水平均显著下降(P<0.05),而治疗后两组患者ALP、AST、CHE指标水平无显著性差异(P>0.05);A组患者不良反应发生率为2.56%较B组的17.95%显著降低(P<0.05)。结论:介入超声下聚桂醇硬化剂治疗肝囊肿可最大限度的将囊腔内的液体抽出,促进患者的恢复,提高临床治疗的效果,减少治疗的费用,并且不良反应少,对肝功能的损伤甚微。Objective:To compare and analyze the clinical effects of lauromacrogol and absolute ethanol in patients with liver cysts under interventional ultrasound;Methods:78 patients with liver cysts admitted from January 2018 to June 2019 were selected and randomly divided into groups A and B.Group A was given lauromacrogol sclerotherapy under interventional ultrasound,and group B was given absolute ethanol sclerotherapy under interventional ultrasound.The clinical efficacy,clinical indicators,liver function indicators,and adverse reactions before and after treatment were compared between the two groups.Results:The total effective rate of clinical efficacy was 97.44%in group A,which was significantly improved compared with 76.92%in group B(P<0.05).The fluid extraction volume(93.78±7.21)mL in group A was significantly higher than that in group B(80.00±7.18)mL.The treatment time was(4.69±0.65)d in group A,significantly shorter than that of group B(7.52±0.62)d.The treatment cost was(4328.27±723.44)yuan in group A,significantly lower than that of group B(4988.98±700.52)yuan.The differences were statistically significant(P<0.05).There were no significant differences in liver function indicators between the patients of the two groups before treatment(P>0.05).The levels of ALP,AST,and CHE indicators in the two groups decreased significantly after treatment(P<0.05).The incidence of adverse reactions in group A was 2.56%,compared with 17.95%in group B(P<0.05);Conclusion:Lauromacrogol sclerosing agent for liver cysts under interventional ultrasound can maximize the effect of the extraction of fluid from the cystic cavity,promote the recovery of patients,improve the effect of clinical treatment,reduce the cost of treatment,and have fewer adverse reactions and minimal damage to liver function.

关 键 词：超声介入 聚桂醇 无水乙醇 肝囊肿 

分 类 号：R73[医药卫生—肿瘤]